Studies evaluating gemtuzumab ozogamicin resistance in acute myeloid leukemia (AML) cells have shown activation of the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) pathway, and inhibition of this pathway with the investigational AKT inhibitor MK-2206 was able to sensitize resistant AML cells to calicheamicin-γ, a DNA-binding cytotoxic antibody and the payload of gemtuzumab ozogamicin (43). This evidence concerns the gene AKT1 and acute myeloid leukemia.